Skip to main content

Table 1 Demographic data of patients with schizophrenia and healthy controls

From: Antipsychotic drugs increase Neuregulin1β1 serum levels in first-episode drug-naïve patients and chronic schizophrenia with suggestions for improving the treatment of psychotic symptoms

 

FEDN patients (n = 69)

Chronic patients with schizophrenia (n = 31)

Controls (n = 79)

F/χ2/t

P

Sex (M/F)

34/35

21/10

44/35

2.960a

0.228

Age (years)

32.68 ± 11.14

40.39 ± 10.35

35.92 ± 11.01

5.434b

0.005

Time in education (years)

10.38 ± 3.59

10.45 ± 3.09

12.48 ± 3.77

7.402b

0.001

BMI (kg/m2)

23.92 ± 2.77

24.51 ± 2.35

23.35 ± 3.36

1.825b

0.164

Smoking

40/29

17/14

35/44

2.932a

0.231

Age schizophrenia onset

30.68 ± 10.81

27.16 ± 10.00

-

1.540c

0.127

Duration of illness (years)

1.98 ± 3.17

12.90 ± 9.04

-

-6.545c

0.000

  1. aχ2 test
  2. bANOVA
  3. cindependent samples t-test
  4. FEDN first-episode drug-naïve, BMI body mass index